#037: Jan 11th, 2022 - Longevity Marketcap Newsletter

1. Announcements

2. Last Week(s) in Longevity

3. Longevity Futures

4. Capital Raise Radar

5. Longevity Jobs

6. New Companies on Longevity List 

7. 2021 Review: Quantifying the Longevity Industry

8. My Links

*Disclaimer: None of this should be taken as financial advice. It is for educational purposes only.

Mission: To grow a wave of passionate people building, funding, and championing technologies that extend healthy human lifespan. 

If you want to be part of this mission alongside me, please consider supporting through Patreon. 

Notice to new readers: You might want to take a look at this post of longevity resources if you are new to this space. 

📢 Announcements

• 📢On Deck Longevity Biotech (ODLB) is now accepting applications for the 2nd cohort.📢

  • Interested in getting involved in the Longevity Biotech startup ecosystem as a founder, early hire, or investor? Apply here.

• My longevity biotech rolling fund Healthspan Capital is now live on Angel List. We’ve raised our first quarter of capital, enlisted an amazing advisory board, and invested in three longevity startups so far. 

  • Our fund is uniquely public and accessible (min $5k) as to allow more sources of capital to enter the private longevity biotech industry.

  • Sebastian Brunemeier (former Principal at Apollo Health Ventures, co-founder of Cambrian Biopharma) is an advisor. Michael Chinen (angel investor) is a partner.

• Feb 3rd, 2022 @10AM PST. Longevity Biotech Virtual Job Fair by On Deck Longevity Biotech. Public job fair featuring longevity biotech startups. Short company intros followed by small group breakout rooms for networking. Companies include: BioAge, Retro Biosciences, Repair Biotechnologies, Rubedo Life Sciences, Gameto, Deciduous Therapeutics, Juvena Therapeutics, Underdog Pharmaceuticals, Arrive Bio, Cognito Therapeutics, and more.

📝 Last Week(s) in Longevity

Industry:

🧬Coinbase CEO, Brian Armstrong, announces $105M funding to launch a new epigenetic reprogramming startup called NewLimit.

* errata: Original publication stated NewLimit’s focus was on radically extending human “lifespan.” This has been corrected to “healthspan”.

The crypto & longevity crossover continues. NewLimit is a newly announced epigenetic reprogramming startup founded by Coinbase founder and CEO, Brian Armstrong, along with Blake Byers (biotech investor formerly at Google Ventures). The company has raised $105M and is focussing on “radically extending human healthspan” by first going after indications in eye disease and immunosenescence using reprogramming before age reversal in all tissues.

With this announcement the